WoundTEK Announces Its S.T.A.R.(TM) Device is helping Heal
US Soldiers Faster from Improvised Explosive Injuries

NEWPORT, RI, Jan. 23 /PRNewswire-FirstCall/ -- WoundTEK, Inc. today announced that the Company has been shipping S.T.A.R. devices to US Military Hospitals for treating active duty soldiers with extremity wounds from Improvised Explosive Devices (IED’s). The biggest threat to US Soldiers in Iraq has become roadside and mobile IED’s. Currently, there are multiple such explosions each day that threaten US and Coalition forces. WoundTEK’s S.T.A.R. device is particularly well suited to treat the wounds typically resulting from such explosions. These extremity wounds (on both legs and arms) are typically treated with a procedure called a fasciotomy, which relives pressure and reduces dangerous swelling to the area. The procedure leaves the patient with very large open wounds that are usually left open for days or up to a week before attempting to close them. The average time to close such wounds at Landstuhl Regional Medical Center in Germany was almost 20 days and often involved a skin grafting procedure. Now the Orthopedic Trauma Surgeons there have been using the S.T.A.R. device to close the wounds on fasciotomy patients and have reduced the time to closure to an average of just 4 days, and almost always avoiding the painful skin graft procedure.

“The United States Military Trauma Surgeons have been amazed with the effectiveness of the device. We are delighted that the patients are receiving a higher level of treatment that is less painful, faster to heal, and greatly decreases the risk of dangerous infections”. Said , President of WoundTEK. He added; “ We are proud to be able to improve the care for our Soldiers who are sacrificing so much for us every day.”

The device has become the standard closure device for the Orthopedic Trauma team at Landstuhl Regional Medical Center in Germany, which is the largest US owned and operated hospital outside the United States borders. The team there is lead by talented Surgeons who are at the forefront of their field and are currently operating one of the top three trauma centers in the world today (measured in number of new patient cases per day).

The S.T.A.R. device is the first minimally invasive tissue expansion device; it is one of the most effective methods for closure of large open wounds caused by trauma or surgery. Its ability to bring large skin deficits to a linear closure rapidly has won the device much acclaim since its introduction and it is rapidly becoming the leading device for most delayed primary closures.

The S.T.A.R. is a class one FDA accepted device and is available through WoundTEK distributors throughout the United States.

With a potential target market for the S.T.A.R. device of almost 2,000,000 procedures annually in the U.S. alone the potential market is in excess of $550 million. Open fractures, decubitus ulcers, burns, and severe trauma, represent the largest areas of opportunity. WoundTEK’s S.T.A.R. device is poised to lead this large and unclaimed market.

About WoundTEK Corporation
WoundTEK is a leading developer and manufacturer of wound closure products with applications in the cardiology, orthopaedics, thoracic, plastic and reconstructive, trauma, and general surgical and wound care markets.

# # #

Cautionary Note for Forward-Looking Statements. This press release contains forward-looking statements that reflect the Company's current expectations about its prospects and opportunities. The Company tried to identify these forward-looking statements by using words such as "expects," "anticipates," "estimates," "plans," "will," "forecasts," or similar expressions, but these words are not the exclusive means for identifying such statements. The Company cautions that a number of risks, uncertainties, and other important factors could cause the Company's actual results to differ materially from those in the forward-looking statements including, without limitation, demand for and the Company's ability to develop and manufacture biomaterial products, additional regulatory approvals, and competition from other technologies in the marketplace. For a more detailed discussion of these and other factors, please see the Company's SEC filings. Except as expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason.